[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transarterial-chemoembolization\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transarterial-chemoembolization":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,41,69,96,123,147,169,194],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100634732","low-dose-bevacizumab-and-atezolizumab-combined-with-tace-haic-in-unresectable-hepatocellular-carcinoma-100634732",false,"NCT07543510","Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma","Efficacy and Safety of Low-Dose Bevacizumab and Atezolizumab Combined With Transarterial Chemoembolization Sequential Hepatic Arterial Infusion Chemotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Single-Arm, Phase II Trial","Inclusion Criteria:\n\nVoluntarily provides written informed consent. Age ≥18 years. Histologically or cytologically confirmed hepatocellular carcinoma (HCC), or clinically diagnosed HCC in patients with cirrhosis according to AASLD criteria.\n\nUnresectable HCC suitable for TACE treatment, including BCLC stage B or C, without Vp4 portal vein tumor thrombus or extrahepatic metastasis.\n\nNo prior systemic therapy for HCC. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Child-Pugh class A or class B7 liver function. No history of autoimmune disease. Life expectancy of at least 3 months. At least one measurable lesion according to RECIST v1.1.\n\nAdequate hematologic, hepatic, and renal function within 1 week before enrollment:\n\nNeutrophils ≥1.5 × 10\\^9\u002FL Platelets ≥50 × 10\\^9\u002FL Hemoglobin ≥90 g\u002FL ALT and AST ≤5 × upper limit of normal (ULN) Serum creatinine ≤1.5 × ULN INR \\\u003C2.3, or prothrombin time ≤ULN + 6 seconds Albumin ≥30 g\u002FL Total bilirubin ≤3 × ULN Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days before enrollment, must not be breastfeeding, and must agree to use effective contraception during the study and for 6 months after the end of study treatment. Men must also agree to use effective contraception during the study and for 6 months after the end of study treatment.\n\nExclusion Criteria:\n\nKnown intrahepatic cholangiocarcinoma, sarcomatoid HCC, mixed cell carcinoma, or fibrolamellar carcinoma; or other active malignancy within 5 years, except adequately treated localized tumors such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the prostate, cervix, or breast.\n\nSevere allergy to iodinated contrast agents that precludes TACE-HAIC treatment. Use of immunosuppressive agents or systemic corticosteroids for immunosuppressive purposes within 1 month before enrollment.\n\nActive infection that cannot be effectively controlled. Severe gastroesophageal varices, or untreated\u002Fincompletely treated varices with bleeding or high bleeding risk.\n\nBrain metastases or bone metastases requiring urgent surgical or radiotherapeutic intervention.\n\nPregnancy, suspected pregnancy, or breastfeeding. Current use of, or recent use within 10 days before study treatment of, aspirin \\>325 mg\u002Fday, dipyridamole, ticlopidine, clopidogrel, or cilostazol.\n\nThrombotic or embolic events within 6 months before treatment initiation, including cerebrovascular accident, transient ischemic attack, cerebral hemorrhage, cerebral infarction, or pulmonary embolism.\n\nCongenital or acquired immunodeficiency. Any of the following within 12 months before study start: myocardial infarction, severe or unstable angina, or congestive heart failure.\n\nRenal failure requiring dialysis. Prior organ transplantation. Any other severe acute or chronic medical or psychiatric condition, or laboratory abnormality, that may increase study risk, interfere with interpretation of results, or make the patient unsuitable for enrollment in the investigator's judgment.","ALL","18 Years",{"count":19,"type":20},38,"ESTIMATED","INTERVENTIONAL",[23],"NA","This is a prospective, single-arm, phase II clinical study designed to evaluate the efficacy and safety of low-dose bevacizumab plus atezolizumab combined with transarterial chemoembolization followed by hepatic arterial infusion chemotherapy (TACE-HAIC) as first-line treatment for patients with unresectable hepatocellular carcinoma (HCC). The study plans to enroll approximately 38 patients with unresectable, locally advanced HCC who have not received prior systemic therapy.\n\nAlthough atezolizumab plus bevacizumab has become a standard first-line treatment option for advanced HCC, the objective response rate remains limited. TACE-HAIC may improve tumor control by increasing local chemotherapy exposure, promoting tumor antigen release, and enhancing the anti-tumor activity of immunotherapy and anti-angiogenic therapy. In this study, patients will receive TACE-HAIC in combination with atezolizumab and low-dose bevacizumab, followed by maintenance treatment with atezolizumab plus low-dose bevacizumab until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-defined discontinuation criteria.\n\nThe primary endpoint is objective response rate (ORR) assessed by investigators according to RECIST version 1.1. Secondary endpoints include ORR by mRECIST, disease control rate, duration of response, progression-free survival, time to progression, overall survival, and safety. This study aims to explore whether this combination strategy can provide improved anti-tumor activity with manageable safety in patients with unresectable HCC.",[26,27,28],"Hepatocellular Carcinoma","Atezolizumab Plus Bevacizumab","Transarterial Chemoembolization","NOT_YET_RECRUITING","2026-04-15",{"date":32,"type":33},"2026-04-22","ACTUAL",{"date":35,"type":20},"2026-05-01",{"date":37,"type":20},"2029-08-31",{"name":39,"class":40},"Third Affiliated Hospital, Sun Yat-Sen University","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100553390","phase-3-tace-plus-camrelizumab-and-apatinib-for-unresectable-hepatocellular-carcinoma-100553390","NCT06485466","TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma","Transarterial Chemoembolization Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma : a Randomised , Open Label, Multicenter Controlled Trial","Inclusion Criteria:\n\n1. Histopathologically or clinically confirmed hepatocellular carcinoma\n2. 18-80 years old.\n3. Performance status (PS) ≤ 1 (ECOG scale).\n4. Barcelona clinical liver cancer (BCLC) stage B or stage C.\n5. Initial treatment of hepatocellular carcinoma.\n6. According to mRECIST, there is at least one measurable lesion.\n7. Child Pugh score ≤ 7.\n8. Participant has sufficient organ and marrow functions.\n9. Expected survival time ≥ 12 weeks.\n10. For women of childbearing age or male patients whose sexual partners are women of childbearing age, effective contraceptive measures should be taken during the whole treatment period and 6 months after the last medication.\n11. Sign the written informed consent, and be able to follow the visit and relevant procedures specified in the plan.\n\nExclusion Criteria:\n\n1. Fibrolamellar carcinoma, sarcomatoid carcinoma, cholangiocarcinoma and other components previously confirmed by histology \u002F cytology.\n2. History of hepatic encephalopathy or liver transplantation.\n3. Pleural effusion, ascites and pericardial effusion with clinical symptoms requiring drainage.\n4. Tumor burden≥70%, diffuse liver cancer or tumor is not suitable for mRECIST standard evaluation.\n5. Received local treatment (ablation therapy, TACE), surgery resection and radiotherapy for liver cancer before the first administration.\n6. Have received systemic chemotherapy, targeted therapy or immunotherapy\n7. There is a significant decrease in white blood cells and platelets in peripheral blood, severe coagulation dysfunction and can not be corrected：the neutrophil\\\u003C1.5×109\u002FL, PLT\\\u003C50×109\u002FL. The INR\\>2.3\n8. Acute or chronic active hepatitis B or C infection, hepatitis B virus (HBV-DNA) \\> 10\\^6 copies \u002F ml; hepatitis C virus (HCV-RNA) \\> 10\\^3 copies \u002F ml; HBsAg and anti HCV antibody were positive at the same time.\n9. There is central nervous system metastasis.\n10. Bleeding of esophageal or gastric varices caused by portal hypertension occurred in the past 6 months, or severe (G3) varices were found in endoscopic examination within 3 months before the first administration, or evidence of portal hypertension (including splenomegaly found in imaging examination) was found. The researchers assessed that the risk of bleeding was high and did not receive sclerotherapy or ligation under the endoscope.\n11. The previous 6-month history of arteriovenous thromboembolism, including myocardial infarction, unstable angina, cerebrovascular accident, pulmonary embolism, deep vein thrombosis or any other serious thromboembolism. The thrombus of implanted vein port or catheter source or superficial vein is stable after routine anticoagulant treatment. Prophylactic use of low-molecular-weight heparin (e.g., enoxaparin 40 mg \u002F day) is permitted.\n12. Tumor thrombus of main portal vein, or involving superior mesenteric vein at the same time.\n13. Aspirin (\\> 325 mg \u002F day) or other drugs known to inhibit platelet function such as dipyridamole or clopidogrel were used for 7 consecutive days within 2 weeks before the first administration.\n14. For uncontrolled hypertension, systolic blood pressure \\> 150 mmHg or diastolic blood pressure \\> 100 mmHg after the best medical treatment, hypertension crisis or hypertension encephalopathy history.\n15. Symptomatic congestive heart failure (New York Heart Association class II-IV). Symptomatic or poorly controlled arrhythmias. The corrected QT interval (QTc) for the history or screening of congenital long QT syndrome was more than 500 ms (calculated by Fridericia method).\n16. Serious bleeding tendency or coagulation dysfunction, or undergoing thrombolysis.\n17. In the past 6 months, there was a history of gastrointestinal perforation and \u002F or fistula, a history of intestinal obstruction (including incomplete intestinal obstruction requiring parenteral nutrition), extensive enterotomy (partial colectomy or extensive enterotomy with chronic diarrhea), Crohn's disease, ulcerative colitis or long-term chronic diarrhea.\n18. Previous and current pulmonary fibrosis history, interstitial pneumonia, pneumoconiosis, drug-related pneumonia, severe impairment of lung function and other lung diseases.\n19. Active tuberculosis (TB), who is receiving anti TB treatment or has received anti TB treatment within one year before the first administration.\n20. People with HIV infection (HIV 1 \u002F 2 antibody positive) and known syphilis infection. Serious infection in active stage or poor clinical control.\n21. Severe infection within 4 weeks before the first administration, including but not limited to hospitalization due to complications of infection, bacteremia or severe pneumonia.\n22. Active autoimmune diseases requiring systemic treatment (such as the use of disease alleviation drugs, corticosteroids or immunosuppressants) occurred within 2 years before the first administration. Alternative therapies (e.g. thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency) are permitted. Known history of primary immunodeficiency. Only the patients with positive autoimmune antibody need to confirm whether there is autoimmune disease according to the judgment of researchers.\n23. Immunosuppressive drugs were used within 4 weeks before the first administration, excluding local glucocorticoids or systemic glucocorticoids (i.e.\n\n    no more than 10 Mg \u002F day prednisone or the equivalent dose of other glucocorticoids), allowing temporary use of glucocorticoids due to dyspnea symptoms in the treatment of asthma, chronic obstructive pulmonary disease and other diseases.\n24. Receive live attenuated vaccine within 4 weeks before the first administration or during the study period.\n25. Major surgical procedures (craniotomy, thoracotomy or open hand) were performed within 4 weeks before the first administration (surgery) or an unhealed wound, ulcer, or fracture.\n26. Uncontrolled \u002F uncorrectable metabolic disorder or other non- malignant organ disease or systemic disease or cancer secondary reaction, which may lead to higher medical risk and \u002F or uncertainty of survival evaluation.\n27. Known to be allergic to any PD-1 monoclonal antibody component.\n28. Women of childbearing age who are unwilling or unable to use acceptable methods of contraception during the whole treatment period of this trial and within 12 weeks after the last administration of the study drug (women of childbearing age include: any women who have had menarche, and have not undergone successful artificial sterilization (hysterectomy, bilateral tubal ligation, or bilateral ovariectomy), pregnancy or lactation Women; women with positive pregnancy test results at the time of inclusion or before study drug administration; If the partner is a woman of childbearing age, the subject is a fertile male without effective contraceptive measures.","80 Years",{"count":50,"type":20},101,[52],"PHASE3","Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third most common cause of cancer-related death worldwide. The majority of patients with HCC are diagnosed as intermediate or advanced stage disease, and not eligible for curative treatments including transplantation, resection, and ablation. Transarterial chemoembolization (TACE) is recommended as first-line treatment for patients with intermediate-stage HCC, while it is also widely used in the unresectable HCC.\n\nThe clinical efficacy and safety in advanced HCC patients of camrelizumab plus apatinib were reported in phase 3 trial (CARES-310). Camrelizumab plus apatinib with a median progression-free survival of 5.7 months and a median overall survival of 22.1 months in advanced HCC.\n\nThis study is randomized, open-label, multicenter controlled trial; which was focused in initial BCLC-B\u002FC HCC patients. This study aimed to compare the efficacy and safety of TACE plus programmed death-1 inhibitor (camrelizumab), and anti-angiogenic therapy (apatinib) with camrelizumab plus apatinib.",[55,28,56,57],"Unresectable Hepatocellular Carcinoma","Camrelizumab","Apatinib","RECRUITING","2026-04-12",{"date":61,"type":33},"2026-04-14",{"date":63,"type":33},"2024-08-10",{"date":65,"type":20},"2028-06-30",{"name":67,"class":40},"Guohui Xu",1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":68},"100590789","qdsa-blood-flow-measurement-in-patients-undergoing-tae-of-the-liver-100590789","NCT06971991","qDSA Blood Flow Measurement in Patients Undergoing TAE of the Liver","qDSA Blood Flow Measurement in Patients Undergoing Transarterial Embolization (TAE) of the Liver","Inclusion Criteria:\n\n* Give voluntary, written informed consent to participate in this study and willing to comply with study-related evaluation and procedure schedule\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Patients with an acute kidney injury or stage IV or V chronic kidney disease (Cr greater than 2.4 or estimated glomerular filtration rate (eGFR) less than 30), unless anuric and on dialysis without expected return of renal function.\n* Patients with an iodinated contrast allergy who cannot be adequately premedicated to receive contrast as part of the embolization procedure.\n* Patients with a physical or psychological condition that would impair study participation.\n* The patient is judged unsuitable for study participation by the Investigator for any other reason",{"count":77,"type":20},20,[23],"The purpose of this research is to evaluate a new technique, quantitative digital subtraction angiography (qDSA), to measure blood flow during liver embolization procedures. Liver embolization is a way of treating liver tumors by blocking blood flow to it. The qDSA technique could help doctors ensure the blood flow to the tumor is decreased by the right amount by calculating blood flow before, during, and after the procedure. Up to 20 participants will be enrolled for 1 study visit and data collection for up to 6 months.",[81,28,82],"Transarterial Embolism","Radioembolization",[84,82,85,86],"Quantitative digital subtraction angiography (qDSA)","TAE","TACE","2026-03-25",{"date":89,"type":33},"2026-03-30",{"date":91,"type":33},"2025-03-13",{"date":93,"type":20},"2026-12",{"name":95,"class":40},"University of Wisconsin, Madison",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":21,"phases":106,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":68},"100625035","phase-3-adjuvant-tace-in-hcc-with-high-risk-recurrence-factors-100625035","NCT07417397","Adjuvant TACE in HCC With High-risk Recurrence Factors","The Efficacy and Safety of Adjuvant TACE in Radical Surgery for Hepatocellular Carcinoma With High-risk Recurrence Factors: A Phase III Randomized Controlled Clinical Study","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1 at enrollment;\n* Child-Pugh class A or B7 (score 5-7);\n* having undergone radical hepatic resection at one of the study centers;\n* histopathologically confirmed HCC;\n* undergo hepatic angiography 4-8 weeks after surgery, with confirmation of no intrahepatic tumor staining;\n* have no prior systemic anti-tumor therapy for HCC;\n* have adequate organ and bone marrow function;\n* estimated life expectancy \\>6 months;\n* present with at least one high-risk factor for recurrence (such as tumor rupture; maximum tumor diameter \\>5 cm; multifocal tumors; microvascular invasion on postoperative pathology; Vp1\u002FVp2 portal vein invasion; lymph node metastasis confirmed by postoperative pathology; positive or narrow surgical margin; and Edmondson grade Ⅲ-Ⅳ differentiation).\n\nExclusion Criteria:\n\n* absence of pathological confirmation of HCC;\n* diagnosis of other malignancies within the 5 years prior to enrollment;\n* a history of hepatic encephalopathy, liver transplantation, pleural effusion, ascites, or pericardial effusion with clinical symptoms after curative hepatectomy, as well as a history of drug allergy, active pulmonary tuberculosis, active syphilis infection, autoimmune disease, or long-term glucocorticoid use;\n* participants who have experienced severe infections within 4 weeks before the first dose, or who have previously received systemic anti-tumor therapy;\n* pregnant or lactating women are ineligible for participation;\n* participants who are unable to comply with the treatment regimen or complete the follow-up requirements.","70 Years",{"count":105,"type":20},442,[52],"The 5-year recurrence rate after curative hepatectomy of hepatocellular carcinoma (HCC) remains as high as 70%. According to the Chinese Liver Cancer Staging (CNLC), transarterial chemoembolization (TACE) is strongly recommended as an adjuvant therapy after curative hepatectomy, aiming to reduce postoperative recurrence and ultimately improve overall survival. However, the effectiveness of such adjuvant postoperative therapy remains controversial. In contrast, guidelines from other countries or regions do not recommend adjuvant TACE after curative hepatectomy. This discrepancy may stem from the fact that adjuvant TACE primarily serves to detect intrahepatic residual lesions via digital subtraction angiography, rather than exerting preventive or therapeutic effects through the embolic agents or chemotherapeutic drugs themselves. This study will evaluate the impact of adjuvant TACE on recurrence-free survival in HCC patients with high-risk recurrence factors who have undergone curative hepatectomy. This study is a Phase III randomized controlled trial in which a total of 442 eligible participants will be randomized in a 1:1 ratio to either the adjuvant TACE group or the intensive follow-up group. The two groups will be compared with respect to recurrence-free survival, overall survival, incidence of treatment-related adverse events and serious adverse events, incidence of treatment discontinuation due to treatment-related adverse events or serious adverse events, median recurrence-free survival, and time to recurrence.",[26,109,28],"Adjuvant",[111,112,113],"transarterial chemoembolization","hepatocellular carcinoma","adjuvant","2026-02-11",{"date":116,"type":33},"2026-02-18",{"date":118,"type":33},"2026-02-01",{"date":120,"type":20},"2029-12-31",{"name":122,"class":40},"Guangxi Medical University",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":21,"phases":133,"briefSummary":134,"conditions":135,"keywords":136,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":146,"locationsCount":4},"100614597","transarterial-chemoembolization-with-low-dose-bevacizumab-plus-atezolizumab-as-first-line-treatment-for-unresectable-hepatocellular-carcinoma-100614597","NCT07281664","Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma","Transarterial Chemoembolization Combined With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase II, Single-Arm Clinical Trial","Inclusion Criteria:\n\n* Age between18 and 75 years;\n* Has a diagnosis of HCC confirmed by radiology, histology, or cytology;\n* Child-Pugh class A;\n* Eastern Cooperative Group performance status (ECOG) score of 0-1;\n* No prior systemic therapy for HCC.\n* Adequate hematologic and end-organ function;\n* At least one measurable intrahepatic target lesion.\n\nExclusion Criteria:\n\n* Diffuse HCC;\n* Cholangiocarcinoma, fibrolamellar, sarcomatoid hepatocellular carcinoma, and mixed hepatocellular\u002Fcholangiocarcinoma subtypes (confirmed by histology, or pathology) are not eligible;\n* Evidence of extrahepatic spread (EHS);\n* Any condition representing a contraindication to TACE or I-125 seeds brachytherapy as determined by the investigators;\n* Evidence or history of bleeding diathesis or any hemorrhage or bleeding event \\>CTCAE grade 3 within 4 weeks prior to randomization;\n* Active or history of autoimmune disease or immune deficiency;\n* Untreated or incompletely treated esophageal and\u002For gastric varices with bleeding or high risk for bleeding;\n* A prior bleeding event due to esophageal and\u002For gastric varices within 6 months prior to initiation of study treatment;\n* Evidence of bleeding diathesis or significant coagulopathy;\n* Pregnant or breastfeeding females;\n* Significant cardiovascular disease;\n* Severe infection, such as active tuberculosis;\n* Serious medical comorbidities;\n* History of organ or cells transplantation;\n* History of other uncurable malignancies.","75 Years",{"count":132,"type":20},30,[23],"This study aims to evaluate the safety and effectiveness of a combined treatment for patients with unresectable hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery. The treatment includes transarterial chemoembolization (TACE), which delivers chemotherapy directly into the liver tumor, together with low-dose bevacizumab and atezolizumab, two medicines that help the immune system fight cancer and inhibit tumor blood vessel growth.\n\nAll participants in this study will receive the same combination treatment as their first-line therapy. The study will observe how well the tumor responds, how long the treatment can control the cancer, and what side effects may occur. The goal is to learn whether this combined approach can provide clinical benefit and improve outcomes for patients with advanced, unresectable liver cancer.",[26,28],[26,137,138,139],"Transarterial chemoembolization","Bevacizumab","Atezolizumab","2025-12-12",{"date":142,"type":33},"2025-12-15",{"date":144,"type":20},"2026-01-01",{"date":120,"type":20},{"name":39,"class":40},{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":130,"enrollmentInfo":153,"targetDuration":4,"studyType":155,"phases":4,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":68},"100608182","drug-eluting-bead-based-transarterial-chemoembolization-deb-tace-as-a-local-salvage-therapy-for-large-lesions-in-relapsed-and-refractory-diffuse-large-b-cell-lymphoma-100608182","NCT07198230","Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma","Inclusion Criteria:\n\n* (1) Age 18 to 75 years; (2) Pathologically confirmed diffuse large B-cell lymphoma (DLBCL); (3) Recurrence or treatment resistance following multiple therapeutic regimens (e.g., chemotherapy, immunotherapy, targeted therapy), with at least one clearly defined bulky lesion (maximum diameter ≥5 cm or imaging evidence of bulky lesion); (4) Imaging studies (CT, MRI, or PET-CT) confirm rich blood supply to the lesion, making it suitable for transarterial interventional therapy; (5) History of favorable response to doxorubicin-based agents during prior systemic therapy; (6) ECOG performance status ≤ 2; (7) Blood counts, hepatic and renal function, and coagulation parameters meet the following criteria:\n\n  * Platelet count ≥ 30 × 10\\^9\u002FL;\n  * Total bilirubin ≤ 1.5 times the upper limit of normal (ULN);\n  * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 times the ULN;\n  * Serum creatinine ≤ 2.5 times the upper limit of normal (ULN);\n  * Prothrombin time international normalized ratio (INR) ≤ 1.5. (8) The patient has previously undergone at least one DEB-TACE treatment at this institution.\n\nExclusion Criteria:\n\n* (1) Patients with severe cardiac, pulmonary, hepatic, or renal dysfunction, or other serious comorbidities rendering them unable to tolerate interventional therapy; (2) Patients with active or uncontrolled severe infections; (3) Patients with severe coagulation disorders or bleeding tendencies; (4) Pregnant or lactating women, or patients planning pregnancy during the study period; (5) Allergy or contraindications to drug-eluting microsphere materials or chemotherapy drugs; (6) Psychiatric disorders or cognitive impairment preventing treatment compliance and follow-up; (7) Other conditions deemed unsuitable for study participation by the investigator.",{"count":154,"type":20},10,"OBSERVATIONAL","Current exploration of local therapies for large Diffuse Large B-Cell Lymphoma (DLBCL) masses remains in its infancy. This study aims to retrospectively evaluate the safety, efficacy, and tolerability of Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) for treating recurrent and refractory DLBCL masses. It seeks to establish a novel local salvage treatment strategy for such patients while providing preliminary theoretical foundations and clinical data to support future large-scale, multicenter clinical trials.",[158,159,28],"Diffuse Large B-Cell Lymphoma","Relapsed and Refractory","2025-11-15",{"date":162,"type":33},"2025-11-18",{"date":164,"type":33},"2025-03-01",{"date":166,"type":20},"2027-09-01",{"name":168,"class":40},"Ting YANG",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":16,"minAge":175,"maxAge":48,"enrollmentInfo":176,"targetDuration":4,"studyType":21,"phases":178,"briefSummary":179,"conditions":180,"keywords":181,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":68},"100606633","effects-of-antrodia-cinnamomea-on-the-hepatoma-patients-after-transcatheter-hepatic-artery-chemoembolization-100606633","NCT07178093","Effects of Antrodia Cinnamomea on the Hepatoma Patients After Transcatheter Hepatic Artery Chemoembolization","Inclusion Criteria:\n\n* Sign the informed consent form\n* Aged between 20 and 80\n* Child-Pugh score class A, B\n* Serum bilirubin level ≤ 1.5 times the upper limit of normal, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels ≤ 2 times the upper limit of normal\n\nExclusion Criteria:\n\n* Unwillingness to sign the informed consent form\n* Child-Pugh score class C\n* Patients with main portal vein thrombosis\n* Patients with diffuse liver tumors\n* Those who are allergic to the contrast medium\n* Those with abnormal coagulation function\n* Those with severe dysfunction of brain, heart and lung\n* Patients with severe renal dysfunction (except those receiving renal dialysis)\n* Unable to cooperate\n* Those with uncontrolled arrhythmia and unstable blood pressure\n* Some patients with abnormal thyroid function\n* Any other contraindications such as active gastrointestinal bleeding, refractory ascites, or severe portal hypertension\n* Pregnant or lactating women","20 Years",{"count":177,"type":20},60,[23],"Effects of Antrodia cinnamomea on the hepatoma patients after Transcatheter hepatic artery chemoembolization",[26,28],[182,112,183,184],"hepatocellular carcinoma (HCC), viral hepatitis, Antrodia cinnamomea, post-TACE syndrome","antrodia cinnamomea","post-TACE syndrome","2025-09-16",{"date":187,"type":33},"2025-09-17",{"date":189,"type":33},"2023-01-01",{"date":191,"type":20},"2025-12-31",{"name":193,"class":40},"Taichung Tzu Chi Hospital",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":130,"enrollmentInfo":200,"targetDuration":202,"studyType":155,"phases":4,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":68},"100576673","prospective-collection-of-therapeutic-efficacy-and-safety-data-in-patients-with-unresectable-hepatocellular-carcinoma-100576673","NCT06788353","Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma","Inclusion Criteria:\n\n1, age 18-75 years old; 2. Patients with primary unresectable liver cancer who have not received any previous treatment (in accordance with the AASLD 2018\u002FEASL 2018 Liver Cancer Diagnostic guidelines); Or patients with unresectable liver cancer who recurred for the first time after radical therapy and did not receive any postoperative adjuvant therapy; 3. There is at least one lesion in the liver that can be measured according to mRECIST criteria, and the intrahepatic lesion is a single tumor ≤10.0cm or multiple tumors (the number of tumors ≤10) and the tumor load is less than 50% (three-dimensional reconstruction of CT scan using Vitelacore software \\[version: 6.9.87.1, Canon\\], calculated as proportion of tumor volume to total liver volume) 4. Normal liver tissue volume exceeds 700ml 5, ECOG score 0-1, good general condition 6, liver function Child-Pugh grade A 7. Expected survival time ≥3 months 8. Blood, liver and kidney function meet the following conditions: a) Neutrophil count ≥1.5×109\u002FL b) Platelet count ≥60×109\u002FL c) Hemoglobin concentration ≥90g\u002FL d) Serum albumin concentration ≥30g\u002FL e) bilirubin ≤50umol\u002FL f) AST and ALT were 5 times lower than the upper limit of normal, ALP less than 4 times the upper limit of normal g) prothrombin time less than 6 seconds above the upper limit of normal h) creatinine less than 1.5 times the upper limit of normal\n\nExclusion Criteria:\n\n1. Preoperative imaging examination assessed tumor load \\>50%;\n2. Previous history of hepatic encephalopathy, refractory ascites, or esophageal and gastric varices rupture bleeding;\n3. There are contraindications for TACE treatment, such as portal shunt, isolated hepatic blood flow, and obvious atherosclerosis;\n4. Patients with extrahepatic metastasis;\n5. Allergic to intravenous contrast agents;\n6. Pregnant or lactating women or subjects who plan to have a family within two years; 7, accompanied by HIV, syphilis infection;\n\n8\\. Accompanied by other malignant tumors or had other malignant tumors within 5 years prior to enrollment; 9. Allogeneic organ transplants; 10, serious heart, kidney and other organ dysfunction; 11. Active clinical severe infection \\> Grade 2; 12. Suffering from mental illness may affect informed consent; 13, can not take oral medicine; 14. Participated in other drug clinical trials within 12 months before enrollment; 15. Active gastric or duodenal ulcer occurred 3 months before enrollment; 16. Previous history of liver or adjacent tissue radiotherapy",{"count":201,"type":20},500,"24 Months","The malignant degree of middle and advanced liver cancer is very high, and the survival prognosis of patients is very poor. TACE is currently the standard treatment for unresectable liver cancer recommended by several international authoritative guidelines. However, TACE can only extend survival from 8 months to 13 months, and the prognosis for patients with unresectable liver cancer is still not optimistic. In recent years, some studies have suggested that the combination of TACE and systemic therapy can prolong OS and PFS, but a number of prospective studies have found that the combination of TACE and targeted therapy can not improve the prognosis of unresectable liver cancer. However, TACE as a non-radical treatment is difficult to achieve complete tumor necrosis, so it is still unknown which treatment combination can best improve the prognosis. This trial is an observational clinical trial to explore the efficacy and safety of TACE combined targeting\u002Fimmunotherapy for unresectable hepatocellular carcinoma. Clinical data of patients with unresectable liver cancer treated in our hospital from March 2023 to March 2025 are intended to be collected to evaluate the efficacy and safety of TACE combined with different systems for unresectable liver cancer.",[28,205,55],"Systemic Therapy","2025-01-19",{"date":208,"type":33},"2025-01-23",{"date":210,"type":33},"2023-03-01",{"date":212,"type":20},"2027-03-01",{"name":214,"class":40},"Sun Yat-sen University"]